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Background/Aims: A risk prediction model for the development of hepatocellular carcinoma (HCC) from indeterminate 
nodules detected on computed tomography (CT) (RadCT score) in patients with chronic hepatitis B (CHB)-related cirrhosis 
was proposed. We validated this model for indeterminate nodules on magnetic resonance imaging (MRI).
Methods: Between 2013 and 2016, Liver Imaging Reporting and Data System (LI-RADS) 2/3 nodules on MRI were 
detected in 99 patients with CHB. The RadCT score was calculated.
Results: The median age of the 72 male and 27 female subjects was 58 years. HCC history and liver cirrhosis were found 
in 47 (47.5%) and 44 (44.4%) patients, respectively. The median RadCT score was 112. The patients with HCC (n=41, 41.4%) 
showed significantly higher RadCT scores than those without (median, 119 vs. 107; P=0.013); the Chinese university-HCC 
and risk estimation for HCC in CHB (REACH-B) scores were similar (both P>0.05). Arterial enhancement, T2 hyperintensity, 
and diffusion restriction on MRI were not significantly different in the univariate analysis (all P>0.05); only the RadCT 
score significantly predicted HCC (hazard ratio [HR]=1.018; P=0.007). Multivariate analysis showed HCC history was the 
only independent HCC predictor (HR=2.374; P=0.012). When the subjects were stratified into three risk groups based on 
the RadCT score (<60, 60–105, and >105), the cumulative HCC incidence was not significantly different among them (all 
P>0.05, log-rank test).
Conclusions: HCC history, but not RadCT score, predicted CHB-related HCC development from LI-RADS 2/3 nodules. New 
risk models optimized for MRI-defined indeterminate nodules are required. (Clin Mol Hepatol 2019;25:390-399)
Keywords: Radiographic image interpretation, Computer-assisted; Liver neoplasms; Hepatitis B; Risk assessment; 
Hepatocellular carcinoma
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IntroduCtIon
Liver cancer is the fifth most common cancer in men (7.9% of 
all cancers), theseventh most common cancer in women (6.5% of 
all cancers),1 and the third most common cause of cancer death 
worldwide.2 In Korea, liver cancer is the second leading cause of 
malignancy mortality, and ~22.5 per 100,000 individuals died of 
hepatocellular carcinoma (HCC).3 Despite recent progress in fol-
low-ups and treatment strategies, the overall prognosis of pa-
tients with HCC has remained dismal (5-year survival rate, <10%) 
owing to the high proportion of patients with advanced HCC.3
If HCC is diagnosed at its late or advanced stage, only palliative 
treatment, such as trans-arterial chemoembolization, molecular 
targeted agent administration, or immunotherapy4 can be applied, 
which results in poor survival. However, if HCC is recognized at its 
early stage, curative treatment options, such as resection, percu-
taneous ablation, or orthotopic liver transplantation, can be con-
sidered, which might yield favorable long-term outcomes.5-8 For 
these reasons, various HCC prediction models, such as the Chi-
nese university (CU)-HCC and risk estimation for HCC in chronic 
hepatitis B (CHB) (REACH-B) models, have been proposed for ear-
ly HCC detection in patients with CHB.2 Recently, magnetic reso-
nance imaging (MRI) using the new liver-specific contrast agent 
gadoxetic acid (Primovist) have been widely used for HCC diagnosis.9,10
Recently, Cho et al.11 proposed a risk prediction model for the 
development of HCC from indeterminate nodules detected on 
computed tomography (CT) (RadCT score) in patients with CHB-re-
lated cirrhosis. Unlike the CU-HCC or REACH-B model, this risk 
model includes radiological findings of “arterial enhancement” on 
CT.11 In their study, indeterminate nodules were categorized into 
three risk groups with significantly different HCC risks (low-risk 
group, 1%; intermediate-risk group, 14.5%; and high-risk group, 
63.1% at 5 years). The Liver Imaging Reporting and Data System 
(LI-RADS)12 subdivides hepatic nodules detected on CT and MRI in 
patients at a high risk for HCC based on their radiological charac-
teristics; indeterminate nodules are subdivided as “probably be-
nign (LR 2),” “intermediate probability (LR 3),” and “probably HCC 
(LR 4)”.12 In a previous study, patients with CHB-related liver cir-
rhosis and indeterminate nodules showed significantly higher risks 
of HCC development.11
In this study, we aimed to validate the previously proposed 
RadCT score for indeterminate nodules (LI-RADS 2/3) detected on 
MRI and compare its accuracy with those of several conventional 
risk prediction models for CHB-related HCC development.
PAtIents And Methods
Patients
Patients with CHB who had LI-RADS 2/3 lesions on MRI con-
ducted at Yonsei Liver Center, Severance Hospital, Yonsei Univer-
sity College of Medicine from 2013 to 2016 were eligible for inclu-
sion in this retrospective cohort study. CHB was defined as 
chronic necroinflammatory disease of the liver caused by persis-
tent infection with hepatitis B virus (HBV), with presence of HBV 
surface antigen in the serum for at least 6 months. LI-RADS 2/3 
nodules were defined on the basis of LI-RADS nodules detected 
on MRI performed for both primary HCC surveillance and diagno-
sis to characterize liver lesions identified on ultrasonography dur-
ing HCC surveillance.12-15
The exclusion criteria were as follows: (1) HCC development <6 
months after enrollment; (2) indeterminate nodules related to pre-
viously treated lesion; (3) co-infection with hepatitis C and human 
immunodeficiency virus; (4) active extrahepatic malignancies; (5) 
other significant medical illness; (6) significant alcohol consump-
tion (>40 g/daily); and (7) insufficient clinical or radiological infor-
mation for statistical analysis. 
The study conformed to the ethical guidelines of the 1975 Dec-
laration of Helsinki and was approved by the institutional review 
board of each institute. The requirement for written informed con-
sent was waived owing to the retrospective nature of the study.
study highlights
•  We attempted to validate the prognostic accuracy of a risk prediction model for the development of hepatocellular carcinoma (HCC) from indeter-
minate nodules detected on computed tomography (RadCT score) for indeterminate nodules on magnetic resonance imaging (MRI).
•  We focused on indeterminate nodules without a definite diagnosis of HCC, which were classified as “probably benign (LR 2)” and “intermediate 
probability (LR 3)” according to the Liver Imaging Reporting and Data System (LI-RADS) guidelines.
•  The RadCT score was not predictive of HCC; conversely, HCC history predicted Chronic hepatitis B-related development of HCC from LI-RADS 2/3 
nodules.
• New risk models optimized for MRI-defined indeterminate nodules are required.
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Baseline data collection
Information on age; sex; other co-morbidities, such as hyper-
tension or diabetes mellitus; body mass index; liver cirrhosis ongo-
ing antiviral therapy (AVT); and HCC history, was collected from 
the medical records. Baseline laboratory parameters, including 
levels of HBV envelope antigen (HBeAg), HBV DNA, alpha-feto-
protein (AFP), aspartate aminotransferase (AST), alanine amino-
transferase (ALT), total bilirubin, and serum albumin and platelet 
counts, were collected. Radiological findings of nodules, such as 
maximal size, arterial enhancement, T2 hyperintensity, and diffu-
sion restriction, were also reviewed. The imaging analysis results 
were interpreted by two expert abdominal radiologists. If the re-
sults were different, the final decision was made after agreement 
between them.
RadCT score
The risk model for the development of HCC from indeterminate 
nodules was recently proposed by Cho et al. (RadCT score).
11 This 
score is composed of seven factors: age, enhancement pattern, 
size, serum albumin level, serum AFP level, HCC history, and 
HBeAg level. The formula for the risk score calculation was as fol-
lows.
Risk score=1×age (years)+19×enhancement pattern (arterial 
non-enhancement or arterioportal shunt=0; arterial enhancement 
=1)+42×size (≤1 cm=0; >1 cm=1)+16×serum albumin level 
(>3.5 g/dL=0; ≤3.5 g/dL=1)+31×serum AFP level (<100 ng/mL=0; 
≥100 ng/mL=1)+32×HCC history (no=0; yes=1)+18×HBeAg level 
(negative=0; positive=1)
Two cutoff values (60 and 105) discriminated the HCC risk into 
three categories. The 3-year HCC development rate was 1%, 
14.5%, and 53.3%, and the 5-year HCC development rate was 
1%, 14.5%, and 63.1% in the low-, intermediate-, and high-risk 
groups, respectively.
CU-HCC and REACH-B scores
The CU-HCC score was first derived in a cohort of 1,005 Chi-
nese patients with CHB.16,17 It is composed of five factors: age, se-
rum albumin level, total bilirubin level, HBV DNA level, and cirrho-
sis and ranges from 0 to 44.5. Two cutoff values (5 and 20) 
discriminated the HCC risk into three categories. The 5-year HCC-
free survival rates were 98.3%, 90.5%, and 78.9% in the low-, 
medium-, and high-risk groups, respectively.
The REACH-B score was derived in 3,584 Chinese patients with 
CHB from the Taiwanese Risk Evaluation of Viral Load Elevation 
and Associated Liver (REVEAL) cohort and validated in a cohort of 
1,505 patients from three tertiary referral clinics in Hong Kong 
and South Korea.16,18 The variables included in the risk score are 
sex, age, serum level of ALT, level of HBeAg, and level of HBV 
DNA. A 17-point risk score was developed, and the HCC risk rate ranged 
from 0% to 47.4% at 5 years and from 0% to 81.6% at 10 years 
for patients with the lowest and highest HCC risks, respectively.
Figure 1. Flow of study population selection. Among 2,748 consecutive patients who underwent liver MRI during the study period, 99 patients were 
selected for the final statistical analysis. MRI, magnetic resonance imaging; LI-RADS, Liver Imaging Reporting and Data System; HCC, hepatocellular car-
cinoma; HCV, hepatitis C virus; HIV, human immunodeficiency virus.
2,748 patients who had liver lesions on MRI
between 2013 and 2016
Patients with LI-RADS 1, 4, and 5 lesions
1.  HCC development less than 6 months after 
enrollement
2. Co-infection with HCV or HIV
3. Active extrahepatic malignancies
4. Other significant medial illness
5. Significant alcohol consumption
6. Insufficient clinical or radiological information
180 patients with LI-RADS 2/3 lesions
99 patients were selected for the final statistical
analysis
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Follow-up and HCC diagnosis 
Although patients with HCC history were included, all partici-
pants were confirmed as being HCC-free at the beginning of the 
study. Each patient was followed up with AFP examination and 
ultrasonography, CT, or MRI every 3 or 6 months for HCC surveil-
lance. Most of the patients have been followed up with ultraso-
nography every 6 months. However, the high-risk patients, for in-
stance, who showed equivocal results based on ultrasonographic 
findings and AFP level received dynamic imaging according to the 
physicians’ decision. Protocols of CT and MRI are described in 
Supplementary Material. During the follow-up, data on the actual 
development to HCC were collected. Two radiologists reviewed 
the dynamic CT and MRI imaging. HCC diagnosis was based on 
the radiological findings on CT and/or MRI or on the histological 
evidence according to the guideline of the American Association 
for the Study of Liver Diseases.19
Statistical analysis
Student’s t-test (or Mann-Whitney test) and the chi-squared test 
(or Fisher’s exact test) were used to compare the baseline charac-
teristics of the patients. In this analysis, we checked the associa-
tion of HCC occurrence with each variable. The patients were cen-
sored at the time of first presentation of HCC or at the last follow-
up. The annual and cumulative incidence of HCC was calculated 
using the Kaplan-Meier method. To identify the independent risk 
factors for HCC development, univariate and subsequent multi-
variate Cox proportional hazard regression analyses were con-
ducted. Hazard ratios (HRs) and corresponding 95% confidence 
intervals (CIs) were presented. The final risk score obtained in the 
RadCT and conventional prediction models, including the CU-HCC 
and REACH-B models, was validated in this cohort. Each risk 
model was validated via Cox regression analyses. All statistical 
analysis was performed using the IBM SPSS statistics software, 
version 24 for Windows (IBM Corp., Armonk, NY, USA).
results
Baseline characteristics 
Among 2,748 consecutive patients who underwent liver MRI 
during the study period, there were 180 patients with LI-RADS 
2/3 lesions. After excluding 81 patients, 99 patients were selected 
for the final statistical analysis (Fig. 1).
The baseline patient characteristics are described in Table 1. 
The median age was 58 years, and the male sex predominated 
(n=72, 72.7%). Liver cirrhosis and HCC history were identified in 
44 (44.4%) and 47 (47.5%) patients, respectively. Of the 47 pa-
tients who had a previous HCC history, 28 patients received cura-
tive treatment (operation [n=22], radiofrequency ablation [n=5], 
and cryoablation [n=1]) and the other 19 patients received non-
table 1. Baseline characteristics
Variable Value
Demographic variables
  Age (years) 58 (51–64)
  Male gender 72 (72.7)
  Hypertension 76 (76.8)
  Diabetes 77 (77.8)
  Body mass index (kg/m2) 24.5 (22.6–26.7)
  Liver cirrhosis 44 (44.4)
  On-going antiviral therapy 62 (62.6)
  Previous HCC history 47 (47.5)
Laboratory variables
  HBeAg positive 29 (29.3)
  HBV DNA (IU/mL) 20 (20–2,030)
  Alpha-fetoprotein (ng/mL) 4.8 (2.3–8.5)
  Aspartate aminotransferase (IU/L) 33.0 (25.0–44.0)
  Alanine aminotransferase (IU/L) 27.0 (20.0–40.0)
  Total bilirubin (mg/dL) 0.9 (0.7–1.3)
  Serum albumin (g/dL) 4.2 (3.9–4.5)
  Platelet count (109/L) 127 (90–161)
Tumor variables
  Maximal size (mm) 11.0 (9.0–15.0)
  Arterial enhancement 16 (16.2)
  T2 hyperintensity 24 (24.2)
  Diffusion restriction 23 (23.2)
Prediction models
  CU-HCC 6 (3–18)
  REACH-B 8 (7–10)
  RADCT score 112 (90–130)
Variables are expressed as median (interquartile range) or n (%).
HCC, hepatocellular carcinoma; HBeAg, hepatitis B virus envelope antigen; 
HBV, hepatitis B virus; DNA, deoxyribonucleic acid; REACH-B, risk estimation 
for hepatocellular carcinoma in chronic hepatitis B; CU, Chinese university; 
RADCT, a risk prediction model for the development of hepatocellular 
carcinoma from indeterminate nodules detected on computed tomography.
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curative treatment (trans-arterial chemoembolization) with the 
achievement of complete response. The median maximal tumor 
size was 11.0 mm. Arterial enhancement, T2 hyperintensity, and 
diffusion restriction were identified in 16 (16.2%), 24 (24.2%), 
and 23 (23.2%) patients, respectively. The median CU-HCC, 
REACH-B, and RadCT scores were 6 (interquartile range [IQR]=3-
18), 8 (IQR=7-10), and 112 (IQR=90-130), respectively.
Comparison between the patients with and without 
HCC
During the follow-up period (median, 20 [IQR=8-29] months), 
the liver lesions in 41 (41.4%) patients progressed to HCC. All 
HCC diagnosis was made according to radiological findings. The 
comparison of the baseline characteristics between the patients 
with and without HCC is shown in Table 2. The disease-free sur-
vival of patients with HCC was significantly shorter than those 
table 2. Comparison between patients who developed HCC and those who did not
Variable
Patients who developed HCC 
(n=41, 41.4%)
Patients who did not develop 
HCC (n=58, 58.6%)
P-value
Demographic variables
  Age (years) 59 (54–63) 57 (50–65) 0.226
  Male gender 30 (73.2) 42 (72.4) 0.934
  Hypertension 12 (29.3) 11 (19.0) 0.232
  Diabetes 11 (26.9) 11 (19.0) 0.354
  Body mass index (kg/m2) 24.1 (22.4–26.8) 25.1 (22.8–26.4) 0.797
  Liver cirrhosis 13 (31.7) 31 (53.4) 0.032
  On-going antiviral therapy 28 (68.3) 34 (58.6) 0.327
  Previous HCC history 27 (65.9) 20 (34.5) 0.002
Laboratory variables
  HBeAg positive 11 (26.8) 18 (31.0) 0.651
  HBV DNA (IU/mL) 20.0 (20.0–126.5) 29.5 (20.0–52,150.0) 0.399
  Alpha-fetoprotein (ng/mL) 6.8 (2.6–14.6) 3.6 (2.0–7.1) 0.790
  Aspartate aminotransferase (IU/L) 29 (25–40) 36 (28–51) 0.031
  Alanine aminotransferase (IU/L) 26 (20–39) 29 (21–42) 0.044
  Total bilirubin (mg/dL) 0.9 (0.6–1.1) 1.0 (0.7–1.4) 0.105
  Serum albumin (g/dL) 4.2 (3.9–4.6) 4.2 (3.9–4.5) 0.526
  Platelet count (109/L) 130 (90–163) 120 (89–164) 0.709
Tumor variables
  Maximal size (mm) 10 (8–15) 11 (9–16) 0.417
  Arterial enhancement 6 (14.6) 10 (17.2) 0.728
  T2 hyperintensity 13 (31.7) 11 (19.0) 0.145
  Diffusion restriction 13 (31.7) 10 (17.2) 0.093
Prediction models
  CU-HCC 3 (3–18) 15 (3–18) 0.285
  REACH-B 8 (7–11) 8 (7–10) 0.991
  RADCT score 119 (95–145) 107 (87–124) 0.013
Variables are expressed as median (interquartile range) or n (%).
HCC, hepatocellular carcinoma; HBeAg, hepatitis B virus envelope antigen; HBV, hepatitis B virus; DNA, deoxyribonucleic acid; REACH-B, risk estimation for 
hepatocellular carcinoma in chronic hepatitis B; CU, Chinese university; RADCT, a risk prediction model for the development of hepatocellular carcinoma from 
indeterminate nodules detected on computed tomography.
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without (median 30 vs. 46 month, P<0.001), but the overall sur-
vival was not significantly different (median 61 vs. 59 months, 
P=0.791).
The patients with HCC had significantly higher proportion of liv-
er cirrhosis (68.3% vs. 58.6%) and HCC history (65.9% vs. 
34.5%) (both P<0.05) than those without. They also had signifi-
cantly lower AST (median, 29 vs. 36 IU/L) and ALT levels (median, 
26 vs. 29 IU/L) and higher RadCT score (median, 120 vs. 98) than 
those without (all P<0.05). The CU-HCC and REACH-B scores 
were significantly similar between them (all P>0.05).
Unadjusted HR of the prediction models for HCC 
development
In contrast to those of the CU-HCC and REACH-B scores (both 
P>0.05), the unadjusted HR of the RADCT score was statistically 
significant for HCC development (HR=1.018, 95% CI=1.005-
1.031, P=0.007) (Table 3). However, when the subjects were 
stratified into three risk groups based on the RadCT score (<60, 
60–105, and >105), the cumulative HCC incidence was not signif-
icantly different among them (overall P=0.536, all P>0.05 among 
adjacent curves, log-rank test) (Fig. 2).
Independent predictors of HCC development
The Cox regression analysis performed to identify the risk fac-
tors associated with development from LI-RADS 2/3 nodules to 
HCC is shown in Table 4. The univariate analysis revealed that liv-
er cirrhosis, HCC history, and the RADCT score were associated 
with HCC development risk (all P<0.05). In contrast, the MRI pa-
rameters, including nodule size, arterial enhancement, T2 hyperin-
tensity, and diffusion restriction, were not predictive of HCC de-
velopment in the univariate analysis (all P >0.05). In the 
subsequent multivariate analysis, HCC history was the only inde-
pendent predictor of HCC development (HR=2.374; 95% 
CI=1.205-4.678; P=0.012). When the subjects were divided into 
two groups according to HCC history, the cumulative incidence of 
HCC was significantly higher in the patients with HCC history than 
in those without (4.2% vs. 23.6% at 1 year; 33.5% vs. 63.4% at 
3 years; P<0.001, log-rank test) (Fig. 3).
dIsCussIon
An accurate assessment of the risk of HCC development is im-
portant for establishing individualized strategies of follow-up, in-
Figure 2. Kaplan-Meier curve for cumulative hepatocellular carcinoma 
(HCC) incidence according to risk groups based on RadCT score. When 
the subjects were stratified into three risk groups based on RadCT score 
(<60, 60–105, and >105), the cumulative HCC incidence was not signifi-
cantly different among them (all P=0.536, log-rank test). 
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table 3. Unadjusted hazard ratio of prediction models
Prediction model Hazard ratio 95% confidence interval P-value
CU-HCC 0.980 0.945–1.046 0.272
REACH-B 1.026 0.923–1.141 0.634
RADCT score 1.018 1.005–1.031 0.007
CU, Chinese university; HCC, hepatocellular carcinoma; REACH-B, risk estimation for hepatocellular carcinoma in chronic hepatitis B; RADCT, a risk prediction 
model for the development of hepatocellular carcinoma from indeterminate nodules detected on computed tomography.
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tervention, and management because this ultimately enables the 
extension of overall survival in patients with CHB.2 To address this 
issue, several risk prediction models for patients with CHB have 
been proposed.2,17,20 In addition, the importance of dysplastic 
nodules as precancerous lesions of HCC is well established. Saka-
moto et al. found that multistep carcinogenesis is one pathway to 
HCC development based on 320 resected liver tissues21; other in-
vestigators also suggested that macroregenerative nodules may 
represent precancerous lesions.22,23 However, because hepatic 
nodular lesions do not necessarily progress to HCC,24-26 it is impor-
tant to identify true precancerous lesions. Thus, a new risk predic-
tion model (RADCT score) for the development of HCC from inde-
terminate nodules on CT in patients with CHB-related cirrhosis 
has been proposed.11
In this study, we attempted to validate the prognostic accuracy 
of the RADCT score. Although the unadjusted HR of the RADCT 
score was statistically significant (HR=1.018, P=0.007), the cumu-
lative risk of HCC development was not significantly different 
among the risk groups after adjustment. Instead, HCC history, one 
of the constituent variables of the RADCT score, was the only pre-
dictor of HCC development. The CU-HCC and REACH-B scores did 
not significantly predict the risk of HCC development. This finding 
suggests that the RADCT score, a new CT-based risk prediction 
model, and conventional risk models for HBV-related HCC devel-
opment in patients with CHB-related cirrhosis, might not be appli-
cable for LI-RADS 2/3 nodules on MRI. Thus, further studies are 
required to optimize the cutoff value for each risk group or estab-
lish another MRI-based prediction model.
Our study has several limitations and strengths. First, we vali-
dated the predictive performance of the RADCT score for indeter-
table 4. Independent predictor of HCC development
Variable
Univariate Multivariate
P-value Hazard ratio 95% confidence interval P-value
Demographic variables
  Age (years) 0.201 - - -
  Male gender 0.477 - - -
  Hypertension 0.069 - - -
  Diabetes 0.118 - - -
  Body mass index (kg/m2) 0.800 - - -
  Liver cirrhosis 0.012 0.566 0.283–1.132 0.107
  On-going antiviral therapy 0.623 - - -
  Previous HCC history 0.002 2.374 1.205–4.678 0.012
Laboratory variables
  HBeAg positive 0.620 - - -
  HBV DNA (IU/mL) 0.349 - - -
  Alpha-fetoprotein (ng/mL) 0.517 - - -
  Aspartate aminotransferase (IU/L) 0.057 - - -
  Alanine aminotransferase (IU/L) 0.125 - - -
  Total bilirubin (mg/dL) 0.150 - - -
  Serum albumin (g/dL) 0.522 - - -
  Platelet count (109/L) 0.720 - - -
Tumor variables
  Maximal size (mm) 0.207 - - -
  Arterial enhancement 0.919 - - -
  T2 hyperintensity 0.081 - - -
  Diffusion restriction 0.185 - - -
HCC, hepatocellular carcinoma; HBeAg, hepatitis B virus envelope antigen; HBV, hepatitis B virus; DNA, deoxyribonucleic acid.
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minate nodules in patients with CHB-related cirrhosis and investi-
gated the prognostic accuracy of other conventional risk 
prediction models. Kobayashi et al.27 reported that 18.8% of 154 
nodules in patients with chronic liver disease progressed to HCC 
during their follow-up period; the cumulative rate of HCC devel-
opment at 5 years was 80.0% for high-grade; 36.6%, low-grade; 
and 12.4%, regenerative dysplastic nodules. However, because 
histological assessments for indeterminate liver nodules are gen-
erally infeasible,28 imaging-based risk assessments, such as use of 
the RADCT score, which is composed of routinely available clinical 
variables, might be appropriate in clinical practice; however, its 
predictive accuracy was not validated in our study.
Second, we focused on indeterminate nodules without a defi-
nite diagnosis of HCC, which were classified as “probably benign 
(LR 2)” and “intermediate probability (LR 3)” according to the LI-
RADS guidelines. LR 2/3 nodules can progress to HCC.27 However, 
in contrast to LR 1 nodules without malignancy risks and LR 4/5 
nodules with high HCC risks, the probability of HCC development 
is in the gray zone, with a relatively low risk of HCC development. 
In our study, 76 out of the 99 patients had only one LI-RADS 2/3 
lesion, whereas the others have more than two LI-RADS 2/3 le-
sions (two in 16 and three in 7 patients). Although several LI-
RADS 2/3 lesions can be found simultaneously in a given patient, 
we considered HCC development as the solid end-points in our 
study, regardless of the number of LI-RADS 2/3 lesions. Indeed, 
the aim of our study was to identify the risk factors of HCC devel-
opment among patients with LI-RADS 2/3 lesions in a clinical 
point of view, not to identify the risk factors of HCC development 
among LI-RADS 2/3 lesions in a radiological point of view. Thus, 
it is important to investigate whether the risk prediction models 
for LR 2/3 nodules can identify high-risk patients who would ben-
efit from more careful monitoring, which might support the ratio-
nale of our study.
Third, although the predictive accuracy was not satisfactory, we 
tested whether the well-known CU-HCC and REACH-B models 
have similar prognostic performances when indeterminate nod-
ules exist in patients with CHB. However, these two models were 
not associated with the risk of HCC development even in the uni-
variate analysis in our cohort; this indicates that the CU-HCC and 
REACH-B models might not be applicable in this clinical setting. 
This finding can be explained in several ways. First, despite the 
low risk of HCC development on MRI, the presence of liver nod-
ules might indicate that the patients already have a higher risk of 
HCC development than those in the cohorts from which the CU-
HCC and REACH-B models were derived. Second, because we at-
tempted to validate the RADCT score, we included patients with 
HCC history to maintain similar clinical characteristics of the study 
cohort. Although we excluded patients who developed HCC im-
mediately after enrollment, HCC history is a strong risk factor of 
HCC development.11,29 Indeed, HCC history was the only predictor 
of HCC development in our study.
There were also several limitations in our study, which remained 
unresolved. First, the CU-HCC and REACH-B models were basical-
ly generated from the cohorts with CHB patients without radio-
logical information regarding the presence of indeterminate he-
patic nodules. This might indicate that the CU-HCC and the 
REACH-B models might have acceptable predictive accuracy, re-
gardless of the potential presence of indeterminate hepatic nod-
ules. Our study focused on only CHB patients with indeterminate 
hepatic nodules by dynamic imaging, who might be not recog-
nized as having indeterminate hepatic nodules by ultrasound. 
Thus, our study population might be a subgroup of the whole 
CHB patients. In addition, due to the different clinical characteris-
tics from the cohorts where CU-HCC and REACH-B models were 
derived, it might be biased to use CU-HCC and REACH-B models 
as controls. However, as these two models are well-known pre-
Figure 3. Kaplan-Meier curve of the cumulative hepatocellular carcino-
ma (HCC) incidence according to HCC history. HCC history was an inde-
pendent predictor of HCC development (hazard ratio=2.374; P=0.012). 
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dictive models, we choose them for comparison.
Second, previous HCC history was selected as a significant pre-
dictor of HCC development in our study. Because Khalili et al.30 
reported that around 20% among 1–2 cm-sized indeterminate 
nodules were finally found to be HCC, our results should be inter-
preted cautiously. Although we included patients who showed 
HCC-free status for at least 6 months to maximize small sample 
size, further large-scale studies are warranted to resolve this is-
sue.
Third, despite the large cohort of patients with CHB before ex-
clusion, only a small proportion was selected for the statistical 
analysis (n=99, 3.6%), and the follow-up period was relatively 
short (median, 20 [IQR=8–29] months). In addition, owing to the 
relatively small sample size, the constituent variables of the RADCT 
score, such as age, enhancement pattern, size, and serum albu-
min, serum AFP, and HBeAg levels, were not predictive of devel-
opment from LI-RADS 2/3 nodules to HCC; this might explain why 
the RADCT score was significant only without adjustment. 
Fourth, liver cirrhosis was not associated with the risk of HCC 
development in our study after adjustment (P=0.107). Although 
we do not know the exact reason, higher proportion of patients 
with AVT which can modify fibrotic burden in spite of morphologi-
cal cirrhosis and small sample size of our cohort might explain this 
phenomenon.
In conclusion, our study validated the prognostic accuracy of a 
newly proposed risk prediction model for development of HCC 
from indeterminate nodules on CT (RADCT score); we found that 
the RadCT score was not predictive of HCC; conversely, HCC histo-
ry predicted CHB-related development of HCC from LI-RADS 2/3 
nodules. New risk models optimized for MRI-defined indetermi-
nate nodules are required.
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